ENvue Medical, Inc. (NASDAQ: FEED) rebrands from NanoVibronix, updates ticker

Rhea-AI Filing Summary

ENvue Medical, Inc., formerly known as NanoVibronix, Inc., has amended its certificate of incorporation to change its corporate name to ENvue Medical, Inc., effective December 12, 2025. On the same date, its common stock stopped trading on Nasdaq under the ticker symbol “NAOV” and began trading under the new symbol “FEED.”

The company states that the name change and ticker change do not affect the rights of its security holders and that its CUSIP remains the same. Under Delaware law, this amendment did not require stockholder approval. The company also issued a press release on December 12, 2025 to announce the name and symbol changes.

false --12-31 0001326706 0001326706 2025-12-08 2025-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 8, 2025

ENvue Medical, Inc.

(Exact name of registrant as specified in its charter)

NanoVibronix, Inc 

Delaware		001-36445		01-0801232
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

969 Pruitt Ave Tyler, Texas		77569
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (914) 233-3004

NanoVibronix, Inc.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		FEED		Nasdaq Capital Market

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On December 8, 2025, the Company filed a Certificate of Amendment to ENvue Medical, Inc. (the “Company”) Certificate of Incorporation (the “Certificate of Amendment”) to change the name of the Company from “NanoVibronix, Inc.” to “ENvue Medical, Inc.” effective as of December 12, 2025 (the “Name Change”). In addition, effective before the open of market trading on December 12, 2025, the Company’s common stock, par value $0.001 per share, ceased trading under the ticker symbol “NAOV” and began trading on the Nasdaq Stock Market under the ticker symbol “FEED” (“Symbol Change”).

Neither the Name Change nor the Symbol Change affects the rights of the Company’s security holders. There will be no change to the Company’s CUSIP in connection with the Name Change or the Symbol Change.

Pursuant to Section 242 of the Delaware General Corporation Law, stockholder approval was not required to complete the Name Change or to approve or effect the Certificate of Amendment. The information set forth herein is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is filed with this report as Exhibit 3.1 and is incorporated by reference herein.

Item 7.01. Regulation FD Disclosure.

On December 12, 2025, the Company issued a press release announcing the Name Change and Symbol Change. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
3.1		Certificate of Amendment of Certificate of Incorporation of ENvue Medical, Inc.
99.1		Press Release, dated December 12, 2025 (furnished pursuant to Item 7.01).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENVUE MEDICAL, INC.
Date: December 12, 2025	By:	/s/ Doron Besser
	Name:	Doron Besser, M.D.
	Title:	Chief Executive Officer

FAQ

What corporate change did ENvue Medical, Inc. (formerly NAOV) report in this 8-K?

The company reported that it changed its corporate name from NanoVibronix, Inc. to ENvue Medical, Inc. through a filed Certificate of Amendment to its certificate of incorporation, effective December 12, 2025.

How did the Nasdaq ticker symbol change for ENvue Medical, Inc. (NAOV)?

Effective before the open of trading on December 12, 2025, the company’s common stock stopped trading under the symbol “NAOV” and began trading on the Nasdaq Stock Market under the symbol “FEED.”

Does the ENvue Medical, Inc. name and symbol change affect shareholder rights?

The company states that neither the name change nor the ticker symbol change affects the rights of its security holders.

Did ENvue Medical, Inc. need stockholder approval for the name change?

No. The company explains that, under Section 242 of the Delaware General Corporation Law, stockholder approval was not required to complete the name change or approve the Certificate of Amendment.

Did ENvue Medical, Inc.’s CUSIP change with the new name and ticker?

No. The company notes there will be no change to its CUSIP in connection with the corporate name change or the ticker symbol change.

How did ENvue Medical, Inc. announce the NAOV to FEED ticker change?

On December 12, 2025, the company issued a press release announcing both the corporate name change to ENvue Medical, Inc. and the Nasdaq ticker symbol change to FEED.